STAT+: FDA announces next round of priority review vouchers
\n \t
\n
<\/BR>
\n
\n \t
\n
<\/BR><\/p>\n
WASHINGTON \u2014\u00a0The Food and Drug Administration on Thursday announced the second batch of companies being granted a \u201cCommissioner\u2019s National Priority Voucher,\u201d a ticket to speedier reviews of drug candidates aligned with U.S. priorities.\u00a0<\/p>\n
The announcement came as the Trump administration unveiled agreements<\/a> with Eli Lilly and Novo Nordisk to reduce the prices of popular weight loss drugs \u2014\u00a0part of a broader effort to show its interest in delivering medications to Americans faster, and at cheaper prices, than in the past.\u00a0<\/p>\n In return for dropping prices, Novo and Lilly each received a priority review voucher, which guarantees a regulatory decision within one to two months. Those vouchers will be used for a\u00a0 slightly different version of Novo\u2019s weight loss drug Wegovy, and Lilly\u2019s orforglipron, an oral weight loss drug based on a different molecule<\/a> than its approved therapy Zepbound.\u00a0\u00a0<\/p>\n Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n